Patents Assigned to Chiesi Farmaceutici S.p.A.
-
Publication number: 20240116947Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: July 14, 2021Publication date: April 11, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Paolo RONCHI, Matteo BIAGETTI, Sara GUARIENTO, Claudio FIORELLI
-
Publication number: 20240116948Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: December 20, 2021Publication date: April 11, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
-
Publication number: 20240092790Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240092791Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
-
Publication number: 20240092792Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 21, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
-
Publication number: 20240082223Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: ApplicationFiled: December 13, 2021Publication date: March 14, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
-
Publication number: 20240025880Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 26, 2021Publication date: January 25, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
-
Publication number: 20240018122Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.Type: ApplicationFiled: July 14, 2021Publication date: January 18, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
-
Publication number: 20240002371Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 26, 2021Publication date: January 4, 2024Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
-
Publication number: 20230416233Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: November 26, 2021Publication date: December 28, 2023Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
-
Patent number: 11844860Abstract: A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa as active ingredients and one or more excipients. Once dispersed in an aqueous medium, melevodopa is completely dissolved, and carbidopa is present as nanoparticles.Type: GrantFiled: February 21, 2019Date of Patent: December 19, 2023Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Ricardo Inacio, Mark Saunders, Bhanvi Mehta, Kathrin Muehlhoelzl-Odoerfer, Isabel Sole Font, Grazia Caivano
-
Publication number: 20230364015Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.Type: ApplicationFiled: July 17, 2023Publication date: November 16, 2023Applicant: Chiesi Farmaceutici S.p.A.Inventors: Daniela COCCONI, Rossella Musa
-
Patent number: 11813360Abstract: The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.Type: GrantFiled: July 24, 2019Date of Patent: November 14, 2023Assignee: CHIESI FARMACEUTICI S.p.A.Inventors: Tomaso Guidi, Amrit Paudel, Sarah Elizabeth Zellnitz, Joana Filipa Fernandes Teixeira Pinto
-
Publication number: 20230277451Abstract: The present invention generally relates to pharmaceutical composition comprising a LABA agent, optionally in combination with other active ingredients, a mixture of at least two inorganic acids, a propellant and a co-solvent. The invention also provides a pharmaceutical composition for the treatment of respiratory diseases, such as asthma and COPD.Type: ApplicationFiled: October 8, 2021Publication date: September 7, 2023Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Enrico ZAMBELLI, Sauro BONELLI, Diego COPELLI, Massimiliano DAGLI ALBERI, Francesca USBERTI
-
Patent number: 11737989Abstract: Provided is a pharmaceutical composition comprising clevidipine in a sterile, ready to use, physically stable, aqueous dispersion of nanoparticles that stabilizes clevidipine against formation of impurities and is suitable for parenteral administration.Type: GrantFiled: May 19, 2015Date of Patent: August 29, 2023Assignee: CHIESI FARMACEUTICI S.P.A.Inventors: Rajeshwar Motheram, David C. Hanley, Sr., Akif Emre Tureli, Monika Kanter
-
Patent number: 11725007Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).Type: GrantFiled: December 12, 2018Date of Patent: August 15, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Alessandro Accetta, Fabio Rancati, Christine Edwards, Gurdip Bhalay, Patrizia Tisselli
-
Patent number: 11723874Abstract: The invention is directed to pharmaceutical compositions such as tablets that exhibit delayed release properties when administered as either whole or half tablets. The invention is also directed to delayed release tablets comprising deferiprone for oral administration, for which twice daily administration is bioequivalent to the same daily dose of an immediate release tablet administered thrice daily. The invention is also directed to methods of making and using the same.Type: GrantFiled: May 21, 2021Date of Patent: August 15, 2023Assignee: Chiesi Farmaceutici S.p.A.Inventors: Bernard Charles Sherman, Michael Spino
-
Publication number: 20230250093Abstract: The present invention relates to compounds of general formula (I) inhibiting lysophosphatidic acid receptor 1 (LPA1), particularly the invention relates to compounds that are Ami do cyclohexane acid derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of LPA receptors, in particular fibrosis.Type: ApplicationFiled: July 15, 2021Publication date: August 10, 2023Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Elisabetta ARMANI, Gabriele AMARI, Andrea RIZZI, Mafalda PAGANO, Luca RAVEGLIA, Claudia BEATO
-
Publication number: 20230227447Abstract: The present invention relates to a compounds of general formula (I) inhibiting DDR1 and DDR2, particularly the invention relates to compounds that are benzylamine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.Type: ApplicationFiled: May 24, 2021Publication date: July 20, 2023Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Bartosz Pawel GUT
-
Publication number: 20230210880Abstract: Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.Type: ApplicationFiled: March 10, 2023Publication date: July 6, 2023Applicant: Chiesi Farmaceutici S. p. A.Inventors: Clive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats